Eosinophils have been mainly associated with parasitic infection and pathologies such as asthma. Some patients with asthma present a high number of eosinophils in their airways. Since respiratory viruses are associated with asthma exacerbations, several studies have evaluated the role of eosinophils against respiratory viruses. Eosinophils contain and produce molecules with antiviral activity, including RNases and reactive nitrogen species. They can also participate in adaptive immunity, serving as antigen-presenting cells. Eosinophil antiviral response has been demonstrated against some respiratory viruses in vitro and in vivo, including respiratory syncytial virus and influenza. Given the implication of respiratory viruses in asthma, the eosinophil antiviral role might be an important factor to consider in this pathology.
Get full access to this article
View all access options for this article.
References
1.
Abdul-CaderMS, AmarasingheA, and Abdul-CareemMF. Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses. Arch Virol, 2016; 161:2075–2086.
2.
AcharyaKR, and AckermanSJ. Eosinophil granule proteins: form and function. J Biol Chem, 2014; 289:17406–17415.
3.
AdamkoDJ, YostBL, GleichGJ, et al.Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection: eosinophils mediate airway hyperresponsiveness, M2 muscarinic receptor dysfunction, and antiviral effects. J Exp Med, 1999; 190:1465–1478.
4.
AlemanF, LimHF, and NairP. Eosinophilic endotype of asthma. Immunol Allergy Clin North Am, 2016; 36:559–568.
5.
Asthma Fact Sheet. World Health Organization, 2017. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma (accessed November2018).
6.
BarnigC, AlsalehG, JungN, et al.Circulating human eosinophils share a similar transcriptional profile in asthma and other hypereosinophilic disorders. PLoS One, 2015; 2;10:e0141740.
7.
BeckerS, ReedW, HendersonFW, et al.RSV infection of human airway epithelial cells causes production of the beta-chemokine RANTES. Am Physiol Soc, 1997; 272:L512–L520.
8.
BjerregaardA, LaingIA, BackerV, et al.High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: a prospective cohort study. Clin Exp Allergy, 2017; 47:1007–1013.
BramleyAM, DasguptaS, SkarbinskiJ, et al.Intensive care unit patients with 2009 pandemic influenza A (H1N1pdm09) virus infection–United States, 2009. Influenza Other Respir Viruses, 2012; 6:e134–e142.
11.
BrancheAR, and FalseyAR. Parainfluenza virus infection. Semin Respir Crit Care Med, 2016; 37:538–554.
12.
BufeA, GehlharK, Grage-GriebenowE, et al.Atopic phenotype in children is associated with decreased virus-induced interferon-α release. Int Arch Allergy Immunol, 2002; 127:82–88.
13.
BuysJ, WeverR, van StigtR, et al.The killing of newborn larvae of Trichinella spiralis by eosinophil peroxidase in vitro. Eur J Immunol, 1981; 11:843–845.
14.
BystromJ, AminK, and Bishop-BaileyD. Analysing the eosinophil cationic protein—a clue to the function of the eosinophil granulocyte. Respir Res, 2011; 12:10.
15.
CampbellHD, TuckerWQ, HortY, et al.Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci U S A, 1987; 84:6629–6633.
16.
CapronM, TorpierG, and CapronA. In vitro killing of S. mansoni schistosomula by eosinophils from infected rats: role of cytophilic antibodies. J Immunol, 1979; 123:2220–2230.
17.
ChuVT, BellerA, RauschS, et al.Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity, 2014; 17;40:582–593.
18.
ContoliM, MessageSD, Laza-StancaV, et al.Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med, 2006; 12:1023–1026.
19.
DavisBP, and RothenbergME. Eosinophils and cancer. Cancer Immunol Res, 2014; 2:1–8.
20.
DavoineF, and LacyP. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol, 2014; 5:570.
21.
del PozoV, de Arruda-ChavesE, de AndrésB, et al.Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase. J Immunol, 1997; 158:859–864.
22.
DentLA, StrathM, MellorAL, et al.Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med, 1990; 172:1425–1431.
23.
DieboldSS, KaishoT, HemmiH, et al.Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004; 303:1529–1531.
24.
DomachowskeJB, DyerKD, AdamsAG, et al.Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res, 1998; 26:3358–3363.
25.
DomachowskeJB, DyerKD, BonvilleCA, et al.Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis, 1998; 177:1458–1464.
26.
DomachowskeJB, and RosenbergHF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev, 1999; 12:298–309.
27.
DrakeMG, Bivins-smithER, ProskocilBJ, et al.Human and mouse eosinophils have antiviral activity against parainfluenza virus. Am J Respir Cell Mol Biol, 2016; 55:387–394.
28.
DuvernelleC, FreundV, and FrossardN. Transforming growth factor-β and its role in asthma. Pulm Pharmacol Ther, 2003; 16:181–196.
29.
DyerKD, PercopoCM, FischerER, et al.Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood, 2009; 114:2649–2656.
30.
EdwardsMR, StrongK, CameronA, et al.Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol, 2017; 140:909–920.
31.
ErikssonCO, GrahamDA, UyekiTM, et al.Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A. Pediatr Crit Care Med, 2012; 13:625–631.
32.
EspíndolaMS, SoaresLS, Galvão-LimaLJ, et al.HIV infection: focus on the innate immune cells. Immunol Res, 2016; 64:1118–1132.
33.
EverardML, SwarbrickA, WrighthamM, et al.Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child, 1994; 71:428–432.
34.
FabreV, BeitingDP, BlissSK, et al.Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol, 2009; 182:1577–1583.
35.
GarofaloR, KimpenJL, WelliverRC, et al.Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. Pediatr Res, 1992; 120:29–32.
36.
GebreselassieNG, MoorheadAR, FabreV, et al.Eosinophils preserve parasitic nematode larvae by regulating local immunity. J Immunol, 2012; 188:417–425.
37.
GleichGJ, FlavahanNA, FujisawaT, et al.The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol, 1988; 81:776–781.
38.
GleichGJ, LoegeringDa, BellMP, et al.Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A, 1986; 83:3146–3150.
39.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available from: www.ginasthma.org (accessed November2018).
40.
GrünigG, WarnockM, WakilAE, et al.Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998; 282:2261–2263.
41.
HamannKJ, GleichGJ, CheckelJL, et al.In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol, 1990; 144:3166–3173.
42.
HandzelZT, BusseWW, SedgwickJB, et al.Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol, 1998; 160:1279–1284.
43.
HanselTT, BraunsteinJB, WalkerC, et al.Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol, 1991; 86:261–267.
44.
HarrisonAM, BonvilleCA, RosenbergHF, et al.Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med, 1999; 159:1918–1924.
HeymannPW, CarperHT, MurphyDD, et al.Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol, 2004; 114:239–247.
47.
HuangL, GebreselassieNG, GagliardoLF, et al.Eosinophils mediate protective immunity against secondary nematode infection. J Immunol, 2015; 194:283–290.
48.
JacksonDJ, GangnonRE, EvansMD, et al.Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med, 2008; 178:667–672.
49.
JacksonDJ, and JohnstonSL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol, 2010; 125:1178–1187.
50.
JacksonDJ, and LemanskeRF. The role of respiratory virus infections in childhood asthma inception. Immunol Allergy Clin North Am, 2010; 30:513–522.
JohanssonMW. Activation states of blood eosinophils in asthma. Clin Exp Allergy, 2014; 44:482–498.
53.
JohnstonSL, PattemorePK, SandersonG, et al.Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ, 1995; 310:1225–1229.
54.
KameyoshiY, DorschnerA, MalletAI, et al.Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med, 1992; 176:587–592.
55.
KatoM, AbrahamRT, OkadaS, et al.Ligation of the beta2 integrin triggers activation and degranulation of human eosinophils. Am J Respir Cell Mol Biol, 1998; 18:675–686.
56.
KimHW, CancholaJG, BrandtCD, et al.Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol, 1969; 89:422–434.
57.
KnottML, MatthaeiKI, GiacominPR, et al.Impaired resistance in early secondary Nippostrongylus brasiliensis infections in mice with defective eosinophilopoeisis. Int J Parasitol, 2007; 37:1367–1378.
58.
KomastuT, IrelandDDC, and ReissCS. IL-12 and viral infections. Cytokine Growth Factor Rev, 1998; 9:277–285.
59.
Kotaniemi-SyrjänenA, VainionpääR, ReijonenTM, et al.Rhinovirus-induced wheezing in infancy—the first sign of childhood asthma?. J Allergy Clin Immunol, 2003; 111:66–71.
60.
KovalszkiA, and WellerPF. Eosinophilia. Prim Care, 2016; 43:607–617.
61.
KvarnhammarAM, PettersonT, and CardellLO. NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Immunology, 2011; 134:314–325.
62.
LeeJJ, JacobsenEA, McGarryMP, et al.Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy, 2010; 40:563–575.
63.
LeeJJ, JacobsenEA, OchkurSI, et al.Human vs. mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol, 2012; 130:572–584.
64.
LeeJJ, McgarryMP, FarmerSC, et al.Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med, 1997; 185:2143–2156.
65.
LehrerRI, SzklarekD, BartonA, et al.Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol, 1989; 142:4428–4434.
66.
LemanskeRF, JacksonDJ, GangnonRE, et al.Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol, 2005; 116:571–577.
67.
LooYM, and GaleM. Immune signaling by RIG-I-like receptors. Immunity, 2011; 34:680–692.
68.
LopezAF, BegleyCG, WilliamsonDJ, et al.Murine eosinophil differentiation factor an eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med, 1986; 163:1085–1099.
69.
LötvallJ, AkdisCA, BacharierLB, et al.Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol, 2011; 127:355–360.
70.
LuceyDR, Nicholson-WellerA, and WellerPF. Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci, 1989; 86:1348–1351.
71.
MathurSK, FichtingerPS, KellyJT, et al.Interaction between allergy and innate immunity: model for eosinophil regulation of epithelial cell interferon expression. Ann Allergy Asthma Immunol, 2013; 111:25–31.
72.
McGarryMP. The evolutionary origins and presence of eosinophils in extant species. In: Lee JJ, Rosenberg HF, (eds.), Eosinophils in Health and Disease. Elsevier, Amsterdam,, 2013:13–18.
73.
McKennaJJ, BramleyAM, SkarbinskiJ, et al.Asthma in patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection-United States, 2009. BMC Infect Dis, 2013; 13:57.
74.
McNamaraPS, RitsonP, SelbyA, et al.Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child, 2003; 88:922–926.
75.
MengelersHJ, MaikoeT, BrinkmanL, et al.Immunophenotyping of eosinophils recovered from blood and BAL of allergic asthmatics. Am J Respir Crit Care Med, 1994; 149:345–351.
76.
MesnilC, RaulierS, PaulissenG, et al.Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest, 2016; 126:3279–3295.
77.
MetcalfD, BurgessAW, JohnsonGR, et al.In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol, 1986; 128:421–431.
78.
MishraA, HoganSP, LeeJJ, et al.Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest, 1999; 103:1719–1727.
79.
MnssonA, FranssonM, AdnerM, et al.TLR3 in human eosinophils: functional effects and decreased expression during allergic rhinitis. Int Arch Allergy Immunol, 2010; 151:118–128.
80.
MontuschiP. Role of leukotrienes and leukotriene modifiers in asthma. Pharmaceuticals, 2010; 3:1792–1811.
81.
MylesP, Nguyen-Van-TamJS, SempleMG, et al.Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J, 2013; 41:824–831.
82.
NagaseH, OkugawaS, OtaY, et al.Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol, 2003; 171:3977–3982.
83.
Nguyen-Van-TamJS, OpenshawPJ, HashimA, et al.Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax, 2010; 65:645–651.
84.
OchkurSI, JacobsenEA, ProtheroeCA, et al.Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol, 2007; 178:7879–7889.
85.
O'ConnellAE, HessJA, SantiagoGA, et al.Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to Strongyloides stercoralis in mice. Infect Immun, 2011; 79:2770–2778.
86.
O'DonnellMC, AckermanSJ, GleichGJ, et al.Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med, 1983; 157:1981–1991.
87.
OhkawaraY, LimKG, XingZ, et al.CD40 expression by human peripheral blood eosinophils. J Clin Invest, 1996; 97:1761–1766.
88.
Olszewska-PazdrakB, PazdrakK, OgraPL, et al.Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J Immunol, 1998; 160:4889–4895.
89.
PadigelUM, LeeJJ, NolanTJ, et al.Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun, 2006; 74:3232–3238.
90.
PapadopoulosNG, ChristodoulouI, RohdeG, et al.Viruses and bacteria in acute asthma exacerbations—a GA 2LEN-DARE* systematic review. Allergy Eur J Allergy Clin Immunol, 2011; 66:458–468.
91.
PercopoCM, DyerKD, OchkurSI, et al.Activated mouse eosinophils protect against lethal respiratory virus infection. Blood, 2014; 123:743–752.
92.
PetrovaVN, and RussellCA. The evolution of seasonal influenza viruses. Nat Rev Microbiol, 2017; 16:47–60.
93.
PhippsS, LamCE, MahalingamS, et al.Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood, 2007; 110:1578–1586.
94.
PiliponskyAM, GleichGJ, NaglerA, et al.Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood, 2003; 101:1898–1904.
95.
PozoVD, de AndrésB, MartínE, et al.Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol, 1992; 22:1919–1925.
96.
PriceDB, RigazioA, CampbellJD, et al.Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med, 2015; 3:849–858.
97.
PrinceGA, CurtisSJ, YimKC, et al.Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol, 2001; 82:2881–2888.
98.
RavinKA, and LoyM. The eosinophil in infection. Clin Rev Allergy Immunol, 2015; 50:214–227.
99.
RimmelzwaanGF, BaarsM, FouchierRAM, et al.Inhibition of influenza virus replication by nitric oxide. Int Congr Ser, 2001; 1219:551–555.
100.
RosenbergHF, BonvilleCA, EastonAJ, et al.The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol Ther, 2005; 105:1–6.
101.
RosenbergHF, and DomachowskeJB. Eosinophils, ribonucleases and host defense: solving the puzzle. Immunol Res, 1999; 20:261–274.
102.
RosenbergHF, DyerKD, and DomachowskeJB. Eosinophils and their interactions with respiratory virus pathogens. Immunol Res, 2009; 43:128–137.
103.
RosenbergHF, DyerKD, and DomachowskeJB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res, 2009; 83:1–9.
104.
RosenbergHF, PhippsSand, and FosterPS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol, 2007; 119:1303–1310.
105.
RotA, KriegerM, BrunnerT, et al.RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med, 1992; 176:1489–1495.
106.
RothenbergME, and HoganSP. The eosinophil. Annu Rev Immunol, 2006; 24:147–174.
107.
RugelesMT, TrubeyCM, BedoyaVI, et al.Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS, 2003; 17:481–486.
108.
Sabogal PiñerosYS, BalSM, van de PolMA, et al.Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B cell and neutrophil responses (MATERIAL): a placebo-controlled, double-blind study. Am J Respir Crit Care Med, 2019; 199:508–517.
109.
SamarasingheAE, MeloRC, DuanS, et al.Eosinophils promote antiviral immunity in mice infected with influenza A virus. J Immunol, 2017; 198:3214–3226.
110.
SamarasingheAE, WoolardSN, BoydKL, et al.The immune profile associated with acute allergic asthma accelerates clearance of influenza virus. Immunol Cell Biol, 2014; 92:449–459.
111.
SandersonCJ. Interleukin-5, eosinophils, and disease. Blood, 1992; 79:3101–3109.
112.
SchönrichG, and RafteryMJ. Neutrophil extracellular traps go viral. Front Immunol, 2016; 7:366.
113.
SedgwickJB, CalhounWJ, VrtisRF, et al.Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol, 1992; 149:3710–3718.
114.
SenGC. Viruses and interferons. Ann Rev Microbiol, 2001; 55:255–281.
115.
ShamriR, XenakisJJ, and SpencerLA. Eosinophils in innate immunity: an evolving story. Cell Tissue Res, 2011; 343:57–83.
116.
ShiHZ, HumblesA, GerardC, et al.Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest, 2000; 105:945–953.
117.
SigursN, GustafssonPM, BjarnasonR, et al.Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med, 2005; 171:137–141.
118.
SimonD, WardlawA, and RothenbergME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol, 2010; 126:3–13.
119.
SlifmanNR, LoegeringDa, McKeanDJ, et al.Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol, 1986; 137:2913–2917.
120.
SongDJ. Rhinovirus and childhood asthma: an update. Korean J Pediatr, 2016; 59:432–439.
121.
SpencerLA, SzelaCT, PerezSAC, et al.Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol, 2008; 85:117–123.
122.
SteinbachKH, SchickP, TrepelF, et al.Estimation of kinetic parameters of neutrophilic, eosinophilic, and basophilic granulocytes in human blood. Blut, 1979; 39:27–38.
123.
SuY-C, TownsendD, HerreroLJ, et al.Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease. J Virol, 2015; 89:1564–1578.
124.
SurS, GlitzDG, KitaH, et al.Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol, 1998; 63:715–722.
125.
SvenningsenS, and NairP. Asthma endotypes and an overview of targeted therapy for asthma. Front Med, 2017; 4:158.
126.
SwartzJM, DyerKD, CheeverAW, et al.Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood, 2006; 108:2420–2427.
127.
SykesA, and JohnstonSL. Etiology of asthma exacerbations. J Allergy Clin Immunol, 2008; 122:685–688.
128.
TaubenbergerJK, and KashJC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe, 2010; 7:440–451.
129.
Vedel-KroghS, NielsenSF, LangeP, et al.Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the copenhagen general population study. Am J Respir Crit Care Med, 2016; 193:965–974.
130.
VeerapandianR, SnyderJD, and SamarasingheAE. Influenza in asthmatics: for better or for worse?. Front Immunol, 2018; 9:1843.
131.
VenturielloSM, GiambartolomeiGH, and ConstantinoSN. Immune cytotoxic activity of human eosinophils against Trichinella spiralis newborn larvae. Parasite Immunol, 1995; 17:555–559.
132.
WangH-B, GhiranI, MatthaeiK, et al.Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol, 2007; 179:7585–7592.
133.
WarkPAB, JohnstonSL, BucchieriF, et al.Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med, 2005; 201:937–947.
134.
WeissSJ, TestST, EckmannCM, et al.Brominating oxidants generated by human eosinophils. Science, 1986; 234:200–203.
135.
WellerPF, RandTH, BarrettT, et al.Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression. J Immunol, 1993; 150:2554–2562.
136.
WellerPF, and SpencerLA. Functions of tissue-resident eosinophils. Nat Rev Immunol, 2017; 17:746–760.
137.
WenzelSE, SchwartzLB, LangmackEL, et al.Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med, 1999; 160:1001–1008.
138.
WhiteMV. The role of histamine in allergic diseases. J Allergy Clin Immunol, 1990; 86:599–605.
139.
WoerlyG, RogerN, LoiseauS, et al.Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med, 1999; 190:487–495.
140.
WongCK, CheungPFY, IpWK, et al.Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol, 2007; 37:85–96.
141.
WuD, MolofskyAB, LiangHE, et al.Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science, 2011; 332:243–247.
142.
YousefiS, GoldJA, AndinaN, et al.Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med, 2008; 14:949–953.
143.
YuC, CantorAB, YangH, et al.targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med, 2002; 195:1387–1395.
